XFOR
NASDAQ · Biotechnology
X4 Pharmaceuticals Inc
$4.64
+0.47 (+11.27%)
Open$4.26
Previous Close$4.17
Day High$4.82
Day Low$4.22
52W High$4.83
52W Low$1.35
Volume—
Avg Volume538.0K
Market Cap393.31M
P/E Ratio—
EPS$-4.58
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+512.5% upside
Current
$4.64
$4.64
Target
$28.42
$28.42
$21.41
$28.42 avg
$38.37
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 82.04M | 38.69M | 57.05M |
| Net Income | -185,054,801 | -510,081,137 | 9.29M |
| Profit Margin | -225.6% | -1,391.4% | 16.3% |
| EBITDA | -200,026,393 | -479,400,827 | 17.50M |
| Free Cash Flow | — | — | 7.43M |
| Rev Growth | — | -5.2% | +3.4% |
| Debt/Equity | 0.41 | 3.41 | 0.94 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |